Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Chief Customer Officer | March 07, 2025 | March 12, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sarepta Therapeutics, Inc.
Report date March 07, 2025 · Filed March 12, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,202 |
Ending reported balance
After 2025-03-10 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2025-03-07 · Exercise / conversion · Acquired 5,500 · Balance 33,659 F1: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. Row 2 · 2025-03-10 · Tax withholding · Disposed 996 · Balance 32,663 F2: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022. Row 3 · 2025-03-10 · Tax withholding · Disposed 2,737 · Balance 29,926 F3: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 7, 2022. Row 4 · 2025-03-10 · Grant · Acquired 8,276 · Balance 38,202 F4: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-03-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-03-07 · Exercise / conversion · Disposed 5,500 · Balance 0 F1: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. |
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.69 · Expires 2035-03-10 | Direct | 16,644 |
Reported balance
After 2025-03-10 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-03-10 · Grant · Acquired 16,644 · Balance 16,644 F5: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.
F2: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.
F3: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 7, 2022.
F4: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date.
F5: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Options (right to buy) · Derivative | 16,644 | $0.00 Strike: $99.69 | $0.00 |
DisclosureSEC source: 0000950170-25-037516 · ownership.xml · derivative · entry 6 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,644 Underlying: Common Stock · 16,644 shares Expires 2035-03-10 F5 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 8,276 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-037516 · ownership.xml · nonDerivative · entry 4 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,202 F4 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 2,737 | $100.13 | $274,055.81 |
DisclosureSEC source: 0000950170-25-037516 · ownership.xml · nonDerivative · entry 3 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,926 F3 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 7, 2022. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 996 | $100.13 | $99,729.48 |
DisclosureSEC source: 0000950170-25-037516 · ownership.xml · nonDerivative · entry 2 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,663 F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 8,613 | $103.70 | $893,168.10 |
DisclosureSEC source: 0000950170-25-036692 · ownership.xml · nonDerivative · entry 3 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,159 F3 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 6, 2023. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 549 | $103.70 | $56,931.30 |
DisclosureSEC source: 0000950170-25-036692 · ownership.xml · nonDerivative · entry 2 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,772 F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023. Read SEC document |
| March 07, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionPerformance Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-037516 · ownership.xml · derivative · entry 5 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. F1 · derivative.exercise_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. F1 · derivative.expiration_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. Read SEC document |
| March 07, 2025 Filed Mar 12, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-037516 · ownership.xml · nonDerivative · entry 1 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. Read SEC document |
| March 06, 2025 Filed Mar 11, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionPerformance Stock Units · Derivative | 17,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-036692 · ownership.xml · derivative · entry 4 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. F1 · derivative.exercise_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. F1 · derivative.expiration_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. Read SEC document |
| March 06, 2025 Filed Mar 11, 2025 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 17,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-036692 · ownership.xml · nonDerivative · entry 1 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,321 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU. Read SEC document |
| March 04, 2025 Filed Mar 7, 2025 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 1,685 | $101.34 | $170,757.90 |
DisclosureSEC source: 0000950170-25-035004 · ownership.xml · nonDerivative · entry 1 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,821 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 711 | $103.77 | $73,780.47 |
DisclosureSEC source: 0000950170-25-032762 · ownership.xml · nonDerivative · entry 1 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,506 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024. F2 · balance_after: Amount of Securities Beneficially Owned includes 194 shares purchased under the Company's registered Employee Stock Purchase Plan on February 28, 2025. Read SEC document |
| February 11, 2025 Filed Feb 14, 2025 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantPerformance Restricted Stock Units · Derivative | 3,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-020192 · ownership.xml · derivative · entry 1 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 3,500 shares Expires not disclosed F1 · derivative.exercise_price: Represents the total number of shares earned under a PSU award granted to the Reporting Person on March 6, 2023. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 6, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F1 · derivative.exercise_date: Represents the total number of shares earned under a PSU award granted to the Reporting Person on March 6, 2023. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 6, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F1 · derivative.expiration_date: Represents the total number of shares earned under a PSU award granted to the Reporting Person on March 6, 2023. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 6, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F1 · derivative.underlying_shares: Represents the total number of shares earned under a PSU award granted to the Reporting Person on March 6, 2023. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 6, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 2,352 | $164.64 | $387,233.28 |
DisclosureSEC source: 0000950170-24-077520 · ownership.xml · nonDerivative · entry 2 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,023 F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 1, 2024. Read SEC document |
| June 21, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionPerformance Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-077520 · ownership.xml · derivative · entry 5 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. F1 · derivative.exercise_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. F1 · derivative.expiration_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. Read SEC document |
| June 21, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantPerformance Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-077520 · ownership.xml · derivative · entry 4 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires not disclosed F1 · derivative.exercise_price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. F1 · derivative.exercise_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. F1 · derivative.expiration_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. Read SEC document |
| June 21, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantPerformance Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-077520 · ownership.xml · derivative · entry 3 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires not disclosed F3 · derivative.exercise_price: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F3 · derivative.exercise_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F3 · derivative.expiration_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Read SEC document |
| June 21, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-077520 · ownership.xml · nonDerivative · entry 1 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,375 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. Read SEC document |
| May 02, 2024 Filed May 7, 2024 00:09 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 3,635 | $140.00 | $508,900.00 |
DisclosureSEC source: 0000950170-24-053837 · ownership.xml · nonDerivative · entry 1 Murray Dallan · CIK 0002022303 · Chief Customer Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,125 F1 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 15, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.